BI 764532 Clinical Trials

2 actively recruiting trials across 1 location

▲ +1 trial since August 2026

Also known as: Obrixtamig

Pipeline

Phase 1: 2

Top Sponsors

Boehringer Ingelheim2

Indications

Cancer2
Small Cell Lung Carcinoma (SCLC)1
Neuroendocrine Neoplasms1
Glioma1
Lung Cancer1

Other1 trial

A Study to Test How BI 764532 is Taken up by Tumours in People With Small-cell Lung Cancer or Neuroendocrine Cancer

Phase 1

Orange, California1 trial

A Study to Test How Well Different Doses of BI 764532 Are Tolerated by People With a Tumour in the Brain That is Positive for DLL3

University of California Irvine

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.